Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 20/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 20/20 | 0.81 |
| ▸ | TACR2 | P21452 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.63 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13244629 | 1.00 | SSTR3 (0.81) | SSTR3KCNH2TACR2PDE4ASSTR1 | |
| SCHEMBL13244681 | 0.93 | SSTR3 (0.70) | SSTR3KCNH2TACR2PDE4ASSTR1 | |
| SCHEMBL3004007 | 0.93 | SSTR3 (0.70) | SSTR3KCNH2TACR2PDE4ASSTR1 | |
| SCHEMBL13244856 | 0.92 | SSTR3 (0.68) | SSTR3KCNH2TACR2PDE4ASSTR1 | |
| SCHEMBL13286436 | 0.92 | SSTR3 (0.81) | SSTR3KCNH2TACR2PDE4ASSTR1 | |
| SCHEMBL13244657 | 0.92 | SSTR3 (0.81) | SSTR3KCNH2TACR2PDE4ASSTR1 | |
| SCHEMBL10108750 | 0.88 | SSTR3 (0.81) | SSTR3KCNH2TACR2PDE4ASSTR1 | |
| SCHEMBL3018513 | 0.88 | SSTR3 (0.82) | SSTR3KCNH2TACR2PDE4ASSTR1 | |
| SCHEMBL13244618 | 0.88 | SSTR3 (0.82) | SSTR3KCNH2TACR2PDE4ASSTR1 | |
| SCHEMBL23777544 | 0.88 | SSTR3 (0.81) | SSTR3KCNH2TACR2PDE4ASSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184758-A1 | BETA CARBOLINE DERIVATIVES AS ANTIDIABETIC COMPOUNDS | GPR119, SSTR3, SSTR2 | SSTR3 2/4885KCNH2 618/4885TACR2 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.